Related Experiment Video
Updated: Nov 14, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
New findings show targeted therapies improve outcomes for renal cell carcinoma (RCC) subtypes. Lenvatinib plus pembrolizumab and cabozantinib demonstrated superior efficacy compared to sunitinib in specific RCC patient groups.
Area of Science:
- Oncology
- Nephrology
- Clinical Trials
Background:
- Renal cell carcinoma (RCC) is a significant cause of cancer-related mortality.
- Treatment options for advanced RCC subtypes remain an area of active research.
- Identifying superior therapeutic strategies for distinct RCC subtypes is crucial for improving patient outcomes.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Kidney Transplant II: Surgical Procedure